Bioconvergence Global Market Report 2025

The bioconvergence market size has grown rapidly in recent years. It will grow from $143.2 billion in 2024 to $159.66 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth during the historic period can be attributed to the rise of personalized medicine, advancements in biomedical engineering, increasing healthcare digitization, the development of bioinformatics, and the collaboration between technology and biotechnology industries.

The bioconvergence market size is expected to see rapid growth in the next few years. It will grow to $243.53 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to the expansion of regenerative medicine applications, rising prevalence of chronic diseases, increased adoption of bioelectronics and biosensors, development of engineered living materials, and a surge in investment in biotechnology research and development. Major trends include the integration of artificial intelligence in drug discovery, advancements in lab-on-a-chip technologies, the growth of wearable biosensors, the expansion of 3D bioprinting applications, the use of nanorobotics for targeted therapies, the adoption of organ-on-a-chip models, and progress in gene editing techniques.

The increasing emphasis on personalized medicine is expected to accelerate the growth of the bioconvergence market. Personalized medicine involves customizing treatments for individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and enhance care. The demand for personalized medicine is rising as genomic technologies advance, allowing for more accurate identification of genetic variations and enabling tailored treatments for individuals. Bioconvergence supports personalized medicine by integrating cutting-edge technologies with biological research, allowing for more precise, individualized treatment plans based on a patient’s genetic and molecular profile. This approach improves healthcare outcomes by facilitating targeted therapies and minimizing adverse effects. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, marking a significant increase from the 12 approved in 2022. Consequently, the growing focus on personalized medicine is driving the bioconvergence market’s expansion.

Leading companies in the bioconvergence market are focusing on the development of innovative products, such as automated miniaturized single-cell proteomics sample preparation, to enable precise protein analysis, minimize sample loss, and streamline workflows in single-cell research. Automated miniaturized single-cell proteomics sample preparation is a process that automates the handling and preparation of proteins from individual cells in ultra-low volumes. For instance, in September 2022, Scienion GmbH, a biotechnology company based in Germany, introduced the Proteochip LF 48, which facilitates reproducible and miniaturized workflows for mass spectrometry-based single-cell proteomics analysis. This advanced bioconvergence tool enables on-chip lysis and protein digestion of individual cells, helping researchers reduce sample loss, simplify workflows, and gain deeper biological insights through efficient mass spectrometry analysis. The Proteochip LF 48 is highly adaptable, offering effective sample preparation for a wide range of single-cell proteomics applications by combining precise cell handling with on-chip lysis and protein digestion, ultimately enhancing workflow efficiency and data quality.

In May 2022, BICO Group AB, a biotechnology company based in Sweden, acquired Allegro 3D Inc. for an undisclosed amount. This acquisition strengthens BICO's bioconvergence portfolio by integrating Allegro 3D’s digital light processing (DLP) technology, which enables high-speed, precise bioprinting for regenerative medicine and drug testing, while also supporting scalable, animal-free tissue development. Allegro 3D Inc., based in the U.S., specializes in DLP bioprinting technology and contributes to bioconvergence through its high-precision tissue engineering and drug testing solutions.

Major players in the bioconvergence market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Veolia Environnement S.A, Novartis AG, Eli Lilly and Company, Amgen Inc., HDR Inc., Ginkgo Bioworks, BICO Group AB, MeMed Diagnostics Ltd., Anima Biotech, Singota Solutions LLC, SetPoint Medical Corporation, Galvani Bioelectronics, Ezassi Inc., Tissue Dynamics Ltd., Sanara Ventures Ltd., BioConvergent Health LLC, Gradiant Bioconvergence Center.

North America was the largest region in the bioconvergence market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Bioconvergence market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bioconvergence is the integration of biology with engineering, data science, and advanced technologies to drive innovation in healthcare, biotechnology, and life sciences. The main objective of bioconvergence is to develop smarter, more personalized, and more efficient solutions such as precision medicine, advanced diagnostics, and bioengineered products. It enables the creation of faster, more cost-effective, and more impactful therapies, devices, and platforms.

The primary components of bioconvergence include devices, software, services, and platforms. Devices refer to hardware or tools that interact with biological systems, combining biology, engineering, and digital technology. This integration involves various advanced technologies such as artificial intelligence, robotics, 3D printing, nanotechnology, synthetic biology, bioinformatics, and wearable devices. These technologies support a wide range of applications, including drug discovery, regenerative medicine, optogenetics, nanorobotics for targeted therapies, diagnostic and biosensing tools, bioelectronics, and precision medicine. Key end users of these innovations include pharmaceutical and biotechnology companies, contract research organizations, and other stakeholders in the healthcare and life sciences industries.

The bioconvergence market research report is one of a series of new reports that provides bioconvergence market statistics, including bioconvergence industry global market size, regional shares, competitors with a bioconvergence market share, detailed bioconvergence market segments, market trends and opportunities, and any further data you may need to thrive in the bioconvergence industry. This bioconvergence market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bioconvergence market consists of revenues earned by entities by providing services such as personalized medicine development, biomedical data analysis, bioinformatics platforms, regenerative medicine solutions, diagnostic technology integration, and smart medical device engineering. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioconvergence market also includes sales of bioprinted tissues and organs, lab-on-a-chip devices, smart implants, bioengineered materials, and integrated diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.